Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TNGX
DateTimeSourceHeadlineSymbolCompany
23/05/202423:18PR Newswire (US)MedivirĀ“s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programNASDAQ:TNGXTango Therapeutics Inc
23/05/202421:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
23/05/202421:00Business WireTango Therapeutics Announces Discontinuation of TNG348 ProgramNASDAQ:TNGXTango Therapeutics Inc
08/05/202421:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
08/05/202421:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
08/05/202421:00Business WireTango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
02/04/202407:48Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
18/03/202422:00Business WireTango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
06/03/202423:00Business WireTango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
06/03/202408:47GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:TNGXTango Therapeutics Inc
09/02/202413:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
09/02/202413:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
07/02/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
06/02/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
06/02/202408:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
31/01/202423:00GlobeNewswire Inc.Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TNGXTango Therapeutics Inc
06/01/202408:05GlobeNewswire Inc.Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
04/01/202418:47PR Newswire (US)MedivirĀ“s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyNASDAQ:TNGXTango Therapeutics Inc
03/01/202423:00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
13/11/202323:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
08/11/202323:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
08/11/202323:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
08/11/202323:00GlobeNewswire Inc.Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
07/11/202323:00GlobeNewswire Inc.Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
03/11/202307:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
19/10/202308:23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
18/09/202321:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:TNGXTango Therapeutics Inc
12/09/202314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TNGXTango Therapeutics Inc
06/09/202321:00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
05/09/202321:00GlobeNewswire Inc.Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TNGXTango Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNGX